Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-06-14
2005-06-14
Leffers, Gerry (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093210, C435S320100, C435S325000, C435S069100, C435S455000, C435S456000, C514S04400A
Reexamination Certificate
active
06905678
ABSTRACT:
Methods and associated materials for transducing mesenchymal stem cells with a desired nucleic acid. Mesenchymal stem cells are a recently discovered kind of stem cell for which suitable transfer vehicles are still desired. Typical gene delivery vehicles such as the adenoviruses or adeno associated viruses have no particular tropism for mesenchymal stem cells. Also disclosed is gene therapy using adenoviruses provided with tropism for mesenchymal stem cells.
REFERENCES:
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6210946 (2001-04-01), Curiel et al.
patent: 6395875 (2002-05-01), Freimuth
patent: 6455314 (2002-09-01), Wickham et al.
patent: 6479290 (2002-11-01), Mehtali et al.
patent: 2003/0053990 (2003-03-01), Rabinowitz et al.
patent: 2003/0077813 (2003-04-01), Freimuth
patent: 1 020 529 (2000-07-01), None
patent: 1 067 888 (2001-01-01), None
patent: 1 279 738 (2003-01-01), None
patent: 02000157289 (2000-06-01), None
patent: WO 00/52186 (2000-09-01), None
Kmiec, E.B. Gene Therapy. May-Jun., 1999. American Scientist, vol. 87, pp 240-247.
Anderson, W.F, Human Gene Therapy. Apr., 1998. Nature, vol. 392, pp 25-30.
Verma, I.M. and Somia, N. Gene Therapy—promises, problems and prospect. Sep., 1997. Nature, vol. 389, pp239-242.
Russell, S.J. Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects, 1994. European J. of Cancer vol. 30(A), pp 1165-1171.
Liu Q and Muruve DA. Molecular Basis of the inflammatory response to adenovirus vectors. Gene Therapy (2003) 10, 935-940.
Stevenson et al., Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular Receptors via the Fiber Head Domain, Journal of Virology,May 1995, pp. 2850-2857, vol. 69, No. 5.
Stevenson et al., Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein, Journal of Virology, Jun. 1997, pp. 4782-4790, vol. 71, No. 6.
Dmitriev et al., An Adenovirus with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism, Journal of Virology, Dec. 1998, pp. 9706-9713, vol. 72, No. 12.
Krasnykh et al., Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism, Journal of Virology, Oct. 1996, pp. 6839-6846, vol. 70, No. 10.
Magnusson et al., Genetic Retargeting of Adenovirus: Novel Strategy Employing “Deknobbing” of the Fiber, Journal of Virology, Aug. 2001, pp. 7280-7289, vol. 75, No. 16.
Conget, P.A., et al., “Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells,” 28 Experimental Hematology 382-390 (2000).
Goossens, P.H., et al., “Infection Efficiency of Type 5 Adenoviral Vectors in Synovial Tissue Can Be Enhanced With a Type 16 Fiber,” 44(3) Arthritis & Rheumatism 570-577 (Mar. 2001).
Havenga, M.J.E., et al., “Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease,” 76(9) Journal of Virology 4612-4620 (May 2002).
Havenga, M.J.E., et al., “Improved Adenovirus Vectors for Infection of Cardiovascular Tissue,” 75(7) Journal of Virology 3335-3342 (Apr. 2001).
Marx, J.C., et al., “High-Efficiency Transduction and Long-Term Gene Expression with a Murine Stem Cell Retroviral Vector Encoding the Green Fluorescent Protein in Human Marrow Stromal Cells,” 10 Human Gene Therapy 1163-1173 (May 1, 1999).
Olmsted-Davis, E.A., et al., “Use of a Chimeric Adenovirus Vector Enhances BMP2 Production and Bone Formation,” 13 Human Gene Therapy 133-1347 (Jul. 20, 2002).
Roelvink, P.W., et al., “Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing Adenovisidae,” 286 Science 1568-1571 (Nov. 1999).
Roelvink, P.W., et al., “The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F,” 72(10) Journal of Virology 7909-7915 (Oct. 1998).
Turgeman, G., et al., “Bone Stem Cell Mediated Gene Therapy and Tissue Engineering,” 15(7) Journal of Bone and Mineral Research S196 (Sep. 2000), Abstract.
Turgeman, G., et al., “Engineered human mesenchymal steam cells: a novel platform for skeletal cell mediated gene therapy,” 3 J. Gene Med. 240-251 (2001).
Viggeswarapu, M., et al., “Adenoviral Delivery of LIM Mineralization Protein-1 Induces New-Bone Formation in Vitro and in Vivo,” 83-A(3) The Journal of Bone & Joint Surgery 364-376 (Mar. 2001).
Yotnda, P., et al., “Efficient infection of primitive hematopoietic stem cells by modified adenovrus,” 8(12) Gene Therapy 930-937 (Jun. 2001).
Bout Abraham
Havenga Menzo Jans Emco
Vogels Ronald
Crucell Holland B.V.
Leffers Gerry
Marvich Maria
TraskBritt
LandOfFree
Gene delivery vectors with cell type specificity for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene delivery vectors with cell type specificity for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene delivery vectors with cell type specificity for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486998